INFLIXIMAB IS A CHIMERIC ANTI-TUMOUR NECROSIS FACTOR-α antibody that is
efficacious in treating Crohn's disease. However, its immunomodulatory properties increase …

Anti-tumor necrosis factor (anti-TNF) therapy is beneficial in the management of many
chronic immune-mediated inflammatory diseases. However, its use is associated with …

Nocardiosis is a serious complication of tumor necrosis factor (TNF) alpha blockers. With the
increasing use of biologics for inflammatory bowel disease, it is to be anticipated that …

Background Infliximab, a chimeric monoclonal immunoglobulin antibody to tumor necrosis
factor-α, has been established as a safe and effective treatment of rheumatoid arthritis …

Human nocardiosis, caused by Nocardia spp., an ubiquitous soil-borne bacteria, is a rare
granulomatous disease close related to immune dysfunctions. Clinically can occur as an …

Adalimumab belongs to the group of tumour necrosis factor‐α inhibitors and has been
approved for the treatment Crohn's Disease since 2007. Herein we report a severe adverse …

Infliximab, an anti-tumor necrosis factor α (TNF-α) antibody, is useful in the treatment of
rheumatoid arthritis, Crohn's disease etc. It has been related to increases in the rate of …

Crohn's disease (CD) is a chronic inflammatory disease that can be associated with
intestinal and extraintestinal manifestations. Some patients are treated with infliximab, an …

BACKGROUND Anti-tumor necrosis factor agents were the first biologic therapy approved
for the management of Crohn's disease (CD). Heart failure (HF) is a rare but potential …

Dear Sir, Opportunistic infections in patients with inflammatory bowel disease are gaining
interest because of the new biologic therapies. We present the case of a Caucasian 53-year …